Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CTH | P32929 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11293073 | 0.79 | CTH (0.44) | EGLN1MAPTALDH1A1TDP1LMNA | |
| SCHEMBL24709385 | 0.79 | CTH (0.44) | EGLN1MAPTALDH1A1TDP1LMNA | |
| SCHEMBL28078070 | 0.75 | TET2 (0.50) | EGLN1ALDH1A1LMNAHSD17B10KDM4E | |
| SCHEMBL15063182 | 0.74 | ECE1 (0.46) | EGLN1LMNAECE1KDM4ESLC22A6 | |
| SCHEMBL322850 | 0.72 | — | — | |
| SCHEMBL10350050 | 0.72 | — | — | |
| SCHEMBL8076846 | 0.72 | — | — | |
| SCHEMBL10391331 | 0.72 | — | — | |
| SCHEMBL10350087 | 0.72 | — | — | |
| N-Oxalylglycine SCHEMBL435820 | 0.71 | EGLN1 (0.56) | EGLN1MAPTALDH1A1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | claimed |
| EP-2341944-A2 | CONJUGATES OF HEXOSE AND METAL COORDINATING COMPOUNDS FOR IMAGING PURPOSES | Mallinckrodt Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2010039609-A2 | A VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | claimed |
| WO-1999021587-A1 | COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1999-05-06 | — | — | WO | claimed |
| US-5760191-A | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | NYCOMED IMAGING AS (NO) | 1998-06-02 | — | — | US | claimed |
| EP-0624097-B1 | TARGETING RADIOACTIVE IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1998-03-18 | — | — | EP | claimed |
| US-5707603-A | Pyridine complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions | NYCOMED IMAGING AS (NO) | 1998-01-13 | — | — | US | claimed |
| EP-0732620-A1 | Composition for developing an exposed photographic product having improved biodegradability | KODAK-PATHE (FR) | 1996-09-18 | — | — | EP | claimed |
| EP-0639083-A1 | COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1995-02-22 | — | — | EP | claimed |
| US-5367080-A | PYRIDINE DERIVATIVES | STERLING WINTHROP INC. (US) | 1994-11-22 | — | — | US | claimed |
| EP-0624097-A1 | TARGETING RADIOACTIVE IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1994-11-17 | — | — | EP | claimed |
| WO-1993021957-A1 | COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS | STERLING WINTHROP INC. (US) | 1993-11-11 | — | — | WO | claimed |
| EP-0487903-B1 | PROCESS FOR THE PREPARATION OF 1,3 PROPANEDIOL | Degussa Aktiengesellschaft (DE) | 1993-04-14 | — | — | EP | claimed |
| US-5171898-A | Hydration of acrolein followed by hydrogenation of formed hydroxyaldehyde; using chelate-forming ion exchange resins, with iminoacid anchoring groups | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1992-12-15 | — | — | US | claimed |
| WO-1992008494-A2 | TARGETING RADIOACTIVE IMMUNOREAGENTS | STERLING WINTHROP INC. (US) | 1992-05-29 | — | — | WO | claimed |
| US-4837169-A | RADIOIMMUNOASSAY | EASTMAN KODAK COMPANY (US) | 1989-06-06 | — | — | US | claimed |
| EP-0288256-A2 | Fluorescent labels | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-10-26 | — | — | EP | claimed |
| JP-1045365-A | — | — | None | — | — | JP | disclosed |
| US-4837169-A | RADIOIMMUNOASSAY | EASTMAN KODAK COMPANY (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0288256-A2 | Fluorescent labels | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | EGLN1 1572/4885MAPT 818/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.